FRLN - Freeline Announces Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201

2023-10-04 07:57:49 ET

(24/7 MARKET NEWS) – Freeline Therapeutics Holdings plc (NASDAQ: FRLN) announced, this morning, positive initial safety, tolerability and enzyme activity data from the ongoing Phase 1/2 GALILEO-1 trial evaluating FLT201, its adeno-associated virus (AAV) gene therapy candidate, in Gaucher disease. Results include robust increases of up to 700-fold over baseline in plasma GCase enzyme activity in first two patients treated with FLT201, normalization of leukocyte GCase in both patients demonstrates cellular uptake from plasma, and FLT201 has been well tolerated, with no serious adverse events

Freeline is trading at $5.12, up $1.36 (+36.17%), on 2.66M premarket shares traded.

Its 52-week range is $2.11 to $12.00. We actually caught this very early in this morning’s move, but were dealing with technical …

The post Freeline Announces Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201 appeared first on 24/7 Market News .

For further details see: